Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies
offer only limited effectiveness. Mutation gene sequencing has shown several gene …

Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

Pancreatic cancer is often detected late, when curative therapies are no longer possible.
Here, we present non-invasive detection of pancreatic ductal adenocarcinoma (PDAC) by 5 …

This guideline presents recommendations for the management of patients with hereditary
gastrointestinal cancer syndromes. The initial assessment is the collection of a family history …

Disclaimer: The practice guidelines of the American College of Medical Genetics and
Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) are developed …

Purpose The main purpose of this study was to determine the prevalence of pathogenic
BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients …

Background: The BRCA1/2 proteins are involved in regulation of cellular proliferation by
DNA damage repair via homologous recombination. Therefore, BRCA1/2 mutation carriers …

BACKGROUND & AIMS: The risk of pancreatic cancer is increased in patients with a strong
family history of pancreatic cancer or a predisposing germline mutation. Screening can …

Purpose An ASCO provisional clinical opinion (PCO) offers timely clinical direction to
ASCO's membership and other health care providers. This PCO addresses identification and …